Fed’s Powell opens door to potential rate cuts at Jackson Hole
ST. LOUIS - Stereotaxis (NYSE:STXS), a leader in robotic technologies for endovascular surgery, has been recognized by NVIDIA at its GPU Technology Conference (GTC) this week in San Jose. NVIDIA, known for its artificial intelligence (AI) and graphics processing prowess, spotlighted Stereotaxis’ advancements in surgical robotics during a special address by its Vice President of Healthcare and Life Sciences. According to InvestingPro data, the company currently maintains a market capitalization of $159 million, operating with a moderate level of debt.
Additionally, Stereotaxis has been welcomed into the NVIDIA Connect program, which will provide the company with access to NVIDIA’s extensive software development resources and industry frameworks. This collaboration is set to bolster Stereotaxis’ efforts in integrating AI into its robotic systems, potentially revolutionizing minimally invasive endovascular interventions.
Stereotaxis’ surgical robots are already utilized by physicians in over 100 leading hospitals worldwide, having treated more than 150,000 patients. The company generated revenue of $26.92 million in the last twelve months, with a robust gross profit margin of 54.22%. The company is now focusing on a new technological phase that emphasizes digital solutions to further enhance its robotic systems. These enhancements include the adoption of AI, robotic automation, data integration, and decision support capabilities. Investments in these areas are already underway, though InvestingPro analysis indicates the company is not yet profitable, with analysts anticipating continued challenges in the near term.
David Fischel, Chairman & CEO of Stereotaxis, expressed gratitude towards NVIDIA for their support in pioneering endovascular robotics. He emphasized the transformative potential of combining AI with the inherent benefits of robotic mechanisms such as precision, safety, and stability in patient treatment.
Stereotaxis is dedicated to the innovation of robotic systems and solutions for the interventional laboratory, aiming to improve patient outcomes, expand access to minimally invasive therapies, and increase efficiency in the operating room. The company’s mission includes the continual discovery, development, and delivery of these advanced technologies.
This news is based on a press release statement and includes forward-looking statements that involve risks and uncertainties. With the stock down 26.29% over the past year and trading near its InvestingPro Fair Value, investors seeking deeper insights can access comprehensive analysis through InvestingPro’s detailed research reports, which include additional financial metrics and expert analysis. Factors that could cause actual results to differ materially include market acceptance of the company’s products, economic conditions affecting customer purchasing decisions, competitive factors, and regulatory approvals, among others. Stereotaxis does not assume any obligation to update these forward-looking statements after the date of release.
In other recent news, Stereotaxis Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $6.3 million, which did not meet the forecasted $8.08 million. The company’s earnings per share (EPS) were reported at -$0.09, missing the expected -$0.06. Despite a 39% year-over-year increase in quarterly revenue, the full-year revenue remained flat at $26.9 million, highlighting ongoing challenges. The company reported an operating loss of $7.6 million, an increase from the previous year’s $5.3 million. Stereotaxis is focusing on expanding its catheter portfolio and anticipates double-digit growth in 2025, with key product launches planned for the second half of the year. The company recently announced FDA submissions for new catheter innovations, indicating strategic transformations underway. Analyst firms like Lake Street Capital Markets and Piper Sandler have been actively engaging with Stereotaxis, reflecting continued interest in the company’s developments. The company’s cash position stands at $12.4 million, with no debt, providing a stable financial base to support its strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.